Exploring Mechanisms of Lipid Nanoparticle‐Mucus Interactions in Healthy and Cystic Fibrosis Conditions
Advanced Healthcare Materials · 2024-07 · 13 (18)
DOI: 10.1002/adhm.202304525 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 13.04.2024. Verfasst von Belal Tafech und 12 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, V6T 1Z3, Canada. Hauptthemen laut MEDLINE: Cystic Fibrosis, Nanoparticles, Mucus, Polyethylene Glycols. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 114 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Providence Health Care, Mitacs.
Abstract (Originalsprache)
Mucus forms the first defense line of human lungs, and as such hampers the efficient delivery of therapeutics to the underlying epithelium. This holds particularly true for genetic cargo such as CRISPR‐based gene editing tools which cannot readily surmount the mucosal barrier. While lipid nanoparticles (LNPs) emerge as versatile non‐viral gene delivery systems that can help overcome the delivery challenge, many knowledge gaps remain, especially for diseased states such as cystic fibrosis (CF). This study provides fundamental insights into Cas9 mRNA or ribonucleoprotein‐loaded LNP‐mucus interactions in healthy and diseased states by assessing the impact of the genetic cargo, mucin sialylation, mucin concentration, ionic strength, pH, and polyethylene glycol (PEG) concentration and nature on LNP diffusivity leveraging experimental approaches and Brownian dynamics (BD) simulations. Taken together, this study identifies key mucus and LNP characteristics that are critical to enabling a rational LNP design for transmucosal delivery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, V6T 1Z3, Canada.
- Department of Chemical and Biological Engineering, University of British Columbia, Vancouver, BC, V6T 1Z4, Canada.
- Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, BC, V6T 1Z3, Canada.
- Acuitas Therapeutics, Vancouver, BC, V6T 1Z3, Canada.
- Centre for Heart Lung Innovation, University of British Columbia, Vancouver, BC, V6T 1Z3, Canada.
- Institute of Pharmacy, Biopharmaceuticals, Freie Universität Berlin, 12169, Berlin, Germany.
ORCID-Profile: Sarah Hedtrich
Förderung
- Deutsche Forschungsgemeinschaft
- Providence Health Care
- Mitacs
- Natural Sciences and Engineering Research Council of Canada
Zitieren
APA
Tafech, B., Rokhforouz, M. R., Leung, J., Sung, M. M., Lin, P. J., Sin, D. D., Lauster, D., Block, S., Quon, B. S., Tam, Y., Cullis, P., Feng, J. J., & Hedtrich, S. (2024). Exploring Mechanisms of Lipid Nanoparticle‐Mucus Interactions in Healthy and Cystic Fibrosis Conditions. Advanced Healthcare Materials, 13(18). https://doi.org/10.1002/adhm.202304525
Vancouver
Tafech B, Rokhforouz MR, Leung J, Sung MM, Lin PJ, Sin DD, et al. Exploring Mechanisms of Lipid Nanoparticle‐Mucus Interactions in Healthy and Cystic Fibrosis Conditions. Advanced Healthcare Materials. 2024;13(18). doi:10.1002/adhm.202304525
BibTeX
@article{Tafech2024,
author = {Tafech, Belal and Rokhforouz, Mohammad-Reza and Leung, Jerry and Sung, Molly Mh and Lin, Paulo Jc and Sin, Don D and Lauster, Daniel and Block, Stephan and Quon, Bradley S and Tam, Ying and Cullis, Pieter and Feng, James J and Hedtrich, Sarah},
title = {Exploring Mechanisms of Lipid Nanoparticle‐Mucus Interactions in Healthy and Cystic Fibrosis Conditions},
journal = {Advanced Healthcare Materials},
year = {2024},
volume = {13},
number = {18},
doi = {10.1002/adhm.202304525}
}
EUVIMED